• Overall Survival of 13.3 months in patients, including 14 months in patients with Grade I/II tumors, suggesting clinical benefit; • Comparison: 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting without BriaCell’s treatment; • Additional overall survival data will be presented at the 2020 San Antonio Breast Cancer Symposium®, …

• Clinical and pathological findings to be presented from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer. BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted …

BERKELEY, Calif., and VANCOUVER, British Columbia, October 1, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer. October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer …

BERKELEY, Calif., and VANCOUVER, British Columbia, September 15, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that Dr. Bill Williams, BriaCell’s President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual …

BERKELEY, Calif., and VANCOUVER, British Columbia, September 4, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that it has received a research grant from the Wiseman Cancer Research Foundation, a 501c(3) nonprofit organization based in Beverly Hills, CA. …

BERKELEY, Calif., and VANCOUVER, British Columbia, August 17, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that further to its news release dated August 11, 2020, it has received the approval of the TSX Venture Exchange for the shares …

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, in combination with pembrolizumab (KEYTRUDA®; manufactured by …

BERKELEY, Calif., and VANCOUVER, British Columbia, August 11, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has entered into a debt settlement agreement (“Debt Settlement”) with a creditor, that has provided legal services to the Company, to …

BERKELEY, Calif., and VANCOUVER, British Columbia, June 24, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining compositions and methods of developing novel …